SCHEMBL7967934

SCHEMBL7967934

O=C(NC1CN(C2CCC(c3ccccn3)CC2)CC1O)N1C(=O)OC[C@@H]1c1ccc(F)c(F)c1

nearest known ligand 0.44

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
ADRA1A P35348 6/20 0.44
ADRA1D P25100 4/20 0.44
ADRA1B P35368 4/20 0.44
CCR2 P41597 4/20 0.36
KCNH2 Q12809 2/20 0.36
CCRL2 O00421 1/20 0.36
SLC6A9 P48067 2/20 0.34
ACKR3 P25106 1/20 0.33
DRD4 P21917 2/20 0.32
BRD4 O60885 3/20 0.32
USP30 Q70CQ3 1/20 0.32
MAP3K5 Q99683 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6964799 0.87 ADRA1A (0.51) ADRA1AADRA1DADRA1BCCR2KCNH2
SCHEMBL7971326 0.87 ADRA1A (0.51) ADRA1AADRA1DADRA1BCCR2KCNH2
SCHEMBL7970730 0.87 ADRA1A (0.51) ADRA1AADRA1DADRA1BCCR2KCNH2
Hydrochloric Acid SCHEMBL7967251 0.86 ADRA1A (0.51) ADRA1AADRA1DADRA1BCCR2KCNH2
Hydrochloric Acid SCHEMBL6964411 0.86 ADRA1A (0.51) ADRA1AADRA1DADRA1BCCR2KCNH2
Hydrochloric Acid SCHEMBL7968249 0.86 ADRA1A (0.51) ADRA1AADRA1DADRA1BCCR2KCNH2
SCHEMBL6966134 0.84 ADRA1D (0.45) ADRA1AADRA1DADRA1BCCR2KCNH2
SCHEMBL7082968 0.79 ADRA1A (0.60) ADRA1AADRA1DADRA1B
SCHEMBL7842959 0.79 ADRA1D (0.44) ADRA1AADRA1DADRA1BCCR2
SCHEMBL6964803 0.75 ADRA1A (0.40) ADRA1AADRA1DADRA1BSLC6A9DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6255315-B1 BENIGN PROSTATIC HYPERPLASIA MERCK & CO., INC. 2001-07-03 US disclosed
US-6037354-A ADMINISTERING PHENYL-SUBSTITUTED THIAZOLIDIN-4-ONE OR OXAZOLIDIN-2-ONE DERIVATIVE TO TREAT BENIGN PROSTATE HYPERPLASIA; SIDE EFFECT REDUCTION MERCK & CO., INC. (US) 2000-03-14 US disclosed